Good Morning Reader,
Pull up (NASDAQ: QNTM) now. Read below...
--
Quantum BioPharma Ltd.
Quantum BioPharma Ltd. (NASDAQ: QNTM) is on a mission to bring breakthrough neuro and metabolic therapies to millions of patients in need. With innovative programs targeting multiple sclerosis (MS) and other high-impact neurological disorders, Quantum is quickly positioning itself at the forefront of the next biotech wave. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing its lead compound, Lucid-MS, a patented oral therapy designed to prevent and reverse myelin degradation — the underlying cause of MS. Preclinical models show compelling potential to restore mobility and function, a feat current treatments can’t claim. Quantum is also leveraging its innovation through the Unbuzzd™ brand, now spun out as Unbuzzd Wellness Inc., where Quantum retains nearly 20% ownership plus up to $250M in royalties from sales. With growing traction in the health and wellness market, this adds a powerful non-dilutive revenue stream to the company’s biotech foundation.
About the Company
Quantum BioPharma is building a next-generation biotech portfolio focused on neurodegenerative, metabolic, and alcohol misuse disorders, powered by a mix of clinical science, digital asset investments, and strategic IP holdings. With its mission to “Develop Novel Solutions for Brain and Inflammatory Disorders,” Quantum’s focus is clear — advancing science, improving lives, and creating value. Backed by a strong financial foundation, a deep IP pipeline, and visionary leadership, QNTM stands as one of the few small-cap biopharma names with both scientific credibility and balance-sheet strength.
Most Notable Catalysts for QNTM:
Strongest Balance Sheet in Company History
● 275% increase in shareholder equity and 86% reduction in debt-to-equity ratio quarter-over-quarter.
● All convertible debentures eliminated, improving liquidity and strengthening fundamentals.
● Management expects current resources to sustain operations beyond March 2027.
Advancing Multiple Sclerosis Drug – Lucid-MS
● Completed Phase 1 toxicity trials with no adverse effects.
● Preparing Phase 2 human trials using its easy-to-administer oral formulation.
● Active collaboration with Massachusetts General Hospital (MGH) validating PET imaging for myelin repair.
Unbuzzd™ Market Growth — Non-Dilutive Upside
● Expanding sales via Amazon and Unbuzzd.com; demand rising quarter-over-quarter.
● Reg D 506(c) raise up to $5M USD ahead of potential IPO.
● Quantum retains equity, royalties, and zero shareholder dilution.
Investigative Spotlight — $700 Million Stock Spoofing Lawsuit
● Featured in a three-part CTV News W5 national investigation uncovering alleged illegal stock manipulation by major Canadian banks.
● Quantum’s leadership continues to defend shareholder interests and market integrity, with a $7M reward offered for verified information aiding litigation.
CEO Zeeshan Saeed stated: “Our goal has always been to bring Lucid-MS to the millions affected by MS — restoring mobility and hope. By standing up to manipulation, we’re protecting our shareholders and the future of this life-changing therapy.”
